The US FDA Office of Chief Counsel’s response to the COVID-19 pandemic has been aided by longstanding professional relationships, an expanded emergency response team and a new way of working with the agency's product centers to expedite release of guidance documents, acting chief counsel Mark Raza said.
Speaking to the Food and Drug Law Institute’s virtual annual meeting on 18 May, Raza talked about the role OCC...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?